NO971900L - Blandinger og behandling av multippel sklerose - Google Patents

Blandinger og behandling av multippel sklerose

Info

Publication number
NO971900L
NO971900L NO971900A NO971900A NO971900L NO 971900 L NO971900 L NO 971900L NO 971900 A NO971900 A NO 971900A NO 971900 A NO971900 A NO 971900A NO 971900 L NO971900 L NO 971900L
Authority
NO
Norway
Prior art keywords
disease
multiple sclerosis
treatment
autoantigen
myelin
Prior art date
Application number
NO971900A
Other languages
English (en)
Norwegian (no)
Other versions
NO971900D0 (no
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of NO971900D0 publication Critical patent/NO971900D0/no
Publication of NO971900L publication Critical patent/NO971900L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO971900A 1994-10-25 1997-04-24 Blandinger og behandling av multippel sklerose NO971900L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
NO971900D0 NO971900D0 (no) 1997-04-24
NO971900L true NO971900L (no) 1997-06-25

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971900A NO971900L (no) 1994-10-25 1997-04-24 Blandinger og behandling av multippel sklerose

Country Status (15)

Country Link
EP (1) EP0787147A1 (sv)
JP (1) JPH10504039A (sv)
AU (1) AU4278296A (sv)
BR (1) BR9509438A (sv)
CA (1) CA2203629A1 (sv)
CZ (1) CZ122697A3 (sv)
FI (1) FI971750A (sv)
HU (1) HUT77047A (sv)
IL (1) IL115766A0 (sv)
IS (1) IS4466A (sv)
NO (1) NO971900L (sv)
PL (1) PL324091A1 (sv)
SI (1) SI9520118A (sv)
SK (1) SK51297A3 (sv)
WO (1) WO1996012737A2 (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
WO1999057241A2 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
EP1490490B1 (en) 2002-03-27 2009-05-13 Aegera Therapeutics Inc. Antisense iap nucleobase oligomers and uses thereof
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP2572734B1 (en) 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF
EP3348275A3 (en) * 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR20120103591A (ko) 2009-10-12 2012-09-19 라이프바이오 라보라토리즈 엘엘씨 다발성 경화증 치료용 조성물
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
EP2688904B1 (en) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
US10188708B2 (en) 2014-01-13 2019-01-29 Berg Llc Enolase 1 (Eno1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
BR9007950A (pt) * 1989-12-20 1992-10-27 Brigham & Womens Hospital Metodo para tratamento ou prevencao da manifestacao de uma doenca auto-imune em um mamifero,formulacao farmaceutica,metodo para tratamento de uma doenca auto-imune,e metodo para tratamento de um mamifero acometido de doenca auto-imune
ATE157257T1 (de) * 1990-03-02 1997-09-15 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
EP0661996A4 (en) * 1991-11-19 1997-05-21 Anergen Inc MHC SUB-UNIT CONJUGATES FOR IMPROVING HARMFUL IMMUNE RESPONSES.
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
ES2172044T3 (es) * 1992-04-09 2002-09-16 Autoimmune Inc Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
JPH08500823A (ja) * 1992-08-17 1996-01-30 オートイミューン インク レトロウィルス関連神経疾患のバイスタンダー抑制
AU7725894A (en) * 1993-09-03 1995-03-22 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
BR9507451A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
CA2189990A1 (en) * 1994-05-10 1995-11-16 Di-Hwei Hsu Compositions and treatment for multiple sclerosis
DK0764273T3 (da) * 1994-06-09 1999-06-23 Tno Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
ATE213499T1 (de) * 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Also Published As

Publication number Publication date
WO1996012737A2 (en) 1996-05-02
IL115766A0 (en) 1996-01-19
AU4278296A (en) 1996-05-15
JPH10504039A (ja) 1998-04-14
IS4466A (is) 1997-04-17
BR9509438A (pt) 1997-12-23
WO1996012737A3 (en) 1996-10-10
NO971900D0 (no) 1997-04-24
CA2203629A1 (en) 1996-05-02
FI971750A0 (sv) 1997-04-24
EP0787147A1 (en) 1997-08-06
HUT77047A (hu) 1998-03-02
CZ122697A3 (en) 1997-09-17
FI971750A (sv) 1997-06-24
SI9520118A (sl) 1998-08-31
PL324091A1 (en) 1998-05-11
SK51297A3 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
NO971900L (no) Blandinger og behandling av multippel sklerose
RU2007102698A (ru) Композиции и способы лечения неврологических нарушений
Neufeld et al. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes
Polman et al. Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat
EP1918298A3 (en) Peptide
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
Petrov et al. Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity
Kardys et al. Experimental allergic encephalomyelitis in Lewis rats: immunoregulation of disease by a single amino acid substitution in the disease-inducing determinant.
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
Ilyas et al. Cellular hypersensitivity to gangliosides and myelin basic protein in multiple sclerosis
US20080207500A1 (en) Medicament
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
Yamada et al. Bombesin-like immunoreactivity in human cerebrospinal fluid
Silfvast Prehospital resuscitation in Helsinki, Finland
Hashim Experimental allergic encephalomyelitis: activation of suppressor T lymphocytes by a modified sequence of the T effector determinant.
Kang et al. Fulminating systemic capillary leak syndrome with lymphocytosis and hypogammaglobulinemia
Kaneko et al. Purification and identification of endogenous anti-opioid substances from bovine brain
JP4160505B2 (ja) 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用
Janković et al. Enkephalinase-inhibitors modulate immune responses
Geovese et al. Giardiasis as a cause of hypokalemic myopathy in congenital immunodeficiency
Eylar et al. Suppression and reversal of allergic encephalomyelitis in rhesus monkeys with basic protein and peptides
Strian et al. Anxiety Depression in Affective Disorders
Kastin et al. DSIP-like immunoreactivity in the developing rat brain
Cotton Options for Multiple Sclerosis Therapy
CA2202496A1 (en) Neurotrophic peptides of activity dependent neurotrophic factor